{"protocolSection":{"identificationModule":{"nctId":"NCT01966003","orgStudyIdInfo":{"id":"20120265"},"secondaryIdInfos":[{"id":"2013-000738-36","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Amgen","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer","officialTitle":"A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2017-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-11-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2015-07-23","type":"ACTUAL"},"completionDateStruct":{"date":"2015-07-23","type":"ACTUAL"},"studyFirstSubmitDate":"2013-10-04","studyFirstSubmitQcDate":"2013-10-16","studyFirstPostDateStruct":{"date":"2013-10-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-09-21","resultsFirstSubmitQcDate":"2017-09-21","resultsFirstPostDateStruct":{"date":"2017-10-19","type":"ACTUAL"},"dispFirstSubmitDate":"2016-03-08","dispFirstSubmitQcDate":"2016-03-08","dispFirstPostDateStruct":{"date":"2016-04-06","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-09-21","lastUpdatePostDateStruct":{"date":"2017-10-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Amgen","class":"INDUSTRY"},"collaborators":[{"name":"Actavis Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer Metastatic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":642,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ABP 215","type":"EXPERIMENTAL","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.","interventionNames":["Drug: Carboplatin","Drug: Paclitaxel","Drug: ABP 215"]},{"label":"Bevacizumab","type":"ACTIVE_COMPARATOR","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.","interventionNames":["Drug: Carboplatin","Drug: Paclitaxel","Drug: Bevacizumab"]}],"interventions":[{"type":"DRUG","name":"Carboplatin","description":"Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W","armGroupLabels":["ABP 215","Bevacizumab"],"otherNames":["Paraplatin"]},{"type":"DRUG","name":"Paclitaxel","description":"Administered 200 mg/m² IV Q3W","armGroupLabels":["ABP 215","Bevacizumab"],"otherNames":["Taxol"]},{"type":"DRUG","name":"ABP 215","description":"Administered 15 mg/kg Q3W by IV infusion","armGroupLabels":["ABP 215"]},{"type":"DRUG","name":"Bevacizumab","description":"Administered 15 mg/kg Q3W by IV infusion","armGroupLabels":["Bevacizumab"],"otherNames":["Avastin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With an Objective Response","description":"Tumor assessments were performed by central, independent, blinded radiologists according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest and abdomen. Objective response is defined as a best overall response of partial response (PR) or complete response (CR) as defined by RECIST v1.1. All participants who did not meet the criteria for CR or PR by the end of the study were considered non-responders.\n\nCR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must be reduced in short axis to \\< 10 mm.\n\nPR: Disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, and no new lesions, or, at least a 30% decrease in the sum of diameters of target lesions, with no progression of existing non-target lesions and no new lesions.","timeFrame":"Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively."}],"secondaryOutcomes":[{"measure":"Duration of Response","description":"Duration of response (DOR) was calculated as the time from the first objective response (PR or CR) to disease progression per RECIST v1.1 based on the central, independent, blinded radiologists' review.\n\nDOR was only calculated for participants with an objective response. For responders not meeting the criterion for progression by the end of the study, DOR was censored at the date of the last evaluable tumor assessment.\n\nProgressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm, or, unequivocal progression of existing non-target lesions, or any new lesions.","timeFrame":"Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively."},{"measure":"Progression-free Survival","description":"Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression using RECIST v1.1 based on the central, independent, blinded radiologists' review, or death. Participants who were alive and did not meet the criteria for progression by the end of the study were censored at their last evaluable disease assessment date. Participants with no evaluable tumor assessments after randomization who did not die by the end of the study were censored on the randomization date.\n\nProgressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm, or, unequivocal progression of existing non-target lesions, or any new lesions.","timeFrame":"From randomization until the end of study; The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively."},{"measure":"Number of Participants With Adverse Events","description":"Adverse events (AEs) were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4, and according to the following scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death due to AE.\n\nA serious adverse event (SAE) is defined as an AE that meets at least 1 of the following serious criteria:\n\n* fatal\n* life-threatening\n* required inpatient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event","timeFrame":"up to 19 weeks"},{"measure":"Number of Participants Who Developed Anti-drug Antibodies","description":"Two validated assays were used to detect the presence of anti-ABP 215 antibodies. Samples were first tested in an electrochemiluminescence (ECL)- based bridging immunoassay to detect antibodies capable of binding to ABP 215 (Binding Antibody Assay). Samples confirmed to be positive for binding antibodies were subsequently tested in a non-cell based target binding assay to determine neutralizing activity against ABP 215 (Neutralizing Antibody Assay). If a post-dose sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the sample was defined as positive for neutralizing antibodies.","timeFrame":"44 weeks (6 months after end of treatment)"},{"measure":"Overall Survival","description":"Overall survival (OS) was defined as the time from the randomization date to date of death. Participants alive at the end of study were censored at the last date known to be alive, derived from dates collected within the study that implied a participant was alive.\n\nParticipants were followed for survival status during the treatment phase and thereafter every 9 weeks until the end of the clinical study, consent was withdrawn, they were lost to follow-up, died, or had proscribed therapy (eg, commercial bevacizumab, non-study anti-cancer treatment).","timeFrame":"From randomization until the end of study; The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC)\n* Subjects must be initiating first-line carboplatin/paclitaxel chemotherapy within 8 days after randomization and expected to receive at least 4 cycles of chemotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1\n\nExclusion Criteria:\n\n* Small cell lung cancer (SCLC) or mixed SCLC and NSCLC\n* Central nervous system (CNS) metastases\n* Malignancy other than NSCLC\n* Palliative radiotherapy for bone lesions inside the thorax\n* Prior radiotherapy of bone marrow\n* Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)\n* Life expectancy \\< 6 months\n* Woman of child-bearing potential who is pregnant or is breast feeding or who is not consenting to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment\n* Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment\n* Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products\n* Other inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"MD","affiliation":"Amgen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Bismarck","state":"North Dakota","zip":"58501","country":"United States","geoPoint":{"lat":46.80833,"lon":-100.78374}},{"facility":"Research Site","city":"Fremantle","state":"Western Australia","zip":"6160","country":"Australia","geoPoint":{"lat":-32.05632,"lon":115.74557}},{"facility":"Research Site","city":"Veliko Tarnovo","state":"Veliko Tarnovo","zip":"5000","country":"Bulgaria","geoPoint":{"lat":43.08124,"lon":25.62904}},{"facility":"Research Site","city":"Rousse","zip":"7003","country":"Bulgaria","geoPoint":{"lat":43.84872,"lon":25.9534}}]},"referencesModule":{"references":[{"pmid":"30617139","type":"DERIVED","citation":"Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, Breder V, Ostoros G, Hanes V. Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. Clin Cancer Res. 2019 Apr 1;25(7):2088-2095. doi: 10.1158/1078-0432.CCR-18-2702. Epub 2019 Jan 7."}],"seeAlsoLinks":[{"label":"AmgenTrials clinical trials website","url":"http://www.amgentrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Eligible participants were randomized in a 1:1 ratio to receive ABP 215 or bevacizumab. Participants were stratified by geographic region (Eastern Europe vs Western Europe vs Asia Pacific/Other vs North America), Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1), and sex.","recruitmentDetails":"This study was conducted at 101 sites (14 sites in the US, 11 in Russia, 10 in Australia, 9 in Germany, 8 in Poland, 7 in Hungary, 7 in Romania, 6 in Italy, 6 in Spain, 5 in Bulgaria, 5 in Greece, 3 in the Czech Republic, 3 in Mexico, 3 in Taiwan, 2 in the Netherlands, 1 in Canada, and 1 in Hong Kong).","groups":[{"id":"FG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"FG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"328"},{"groupId":"FG001","numSubjects":"314"}]},{"type":"Received Study Drug","achievements":[{"groupId":"FG000","numSubjects":"324"},{"groupId":"FG001","numSubjects":"309"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"44"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"270"},{"groupId":"FG001","numSubjects":"270"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"36"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"Plan to Receive Other Anticancer Therapy","reasons":[{"groupId":"FG000","numSubjects":"131"},{"groupId":"FG001","numSubjects":"127"}]},{"type":"Plan to Receive Commercial Bevacizumab","reasons":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"67"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"BG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"328"},{"groupId":"BG001","value":"314"},{"groupId":"BG002","value":"642"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.6","spread":"9.09"},{"groupId":"BG001","value":"61.6","spread":"8.88"},{"groupId":"BG002","value":"61.6","spread":"8.98"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"< 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"191"},{"groupId":"BG002","value":"390"}]}]},{"title":"≥ 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"252"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"258"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"196"},{"groupId":"BG001","value":"188"},{"groupId":"BG002","value":"384"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"30"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"314"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"612"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"Participants were allowed to choose multiple races.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"315"},{"groupId":"BG001","value":"300"},{"groupId":"BG002","value":"615"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}]}]},{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]},{"title":"Native Hawaiian or other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}]}]},{"title":"Geographic Region","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Eastern Europe","categories":[{"measurements":[{"groupId":"BG000","value":"189"},{"groupId":"BG001","value":"186"},{"groupId":"BG002","value":"375"}]}]},{"title":"Western Europe","categories":[{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"154"}]}]},{"title":"North America","categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"57"}]}]},{"title":"Asia Pacific/Other","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"56"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self care, unable to carry out any work activities. Up and about \\> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \\> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Grade 0","categories":[{"measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"244"}]}]},{"title":"Grade 1","categories":[{"measurements":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"197"},{"groupId":"BG002","value":"398"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With an Objective Response","description":"Tumor assessments were performed by central, independent, blinded radiologists according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest and abdomen. Objective response is defined as a best overall response of partial response (PR) or complete response (CR) as defined by RECIST v1.1. All participants who did not meet the criteria for CR or PR by the end of the study were considered non-responders.\n\nCR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes must be reduced in short axis to \\< 10 mm.\n\nPR: Disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, and no new lesions, or, at least a 30% decrease in the sum of diameters of target lesions, with no progression of existing non-target lesions and no new lesions.","populationDescription":"Intent-to-treat population which consisted of all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.","groups":[{"id":"OG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"OG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"314"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0"},{"groupId":"OG001","value":"41.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The risk ratio (ABP 215/Bevacizumab) and 90% confidence interval (CI) were estimated using a generalized linear model adjusted for the stratification factors (region, sex, and ECOG performance status).","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"Clinical equivalence of the primary endpoint was demonstrated by comparing the 2-sided 90% CI of the risk ratio in objective response rate between ABP 215 and bevacizumab with an equivalence margin of (0.67, 1.5).","paramType":"Risk Ratio (RR)","paramValue":"0.93","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.80","ciUpperLimit":"1.09"},{"groupIds":["OG000","OG001"],"groupDescription":"Risk difference (ABP 215 - Bevacizumab) and 90% CI were estimated using a generalized linear model adjusted for the randomization stratification factors geographic region, ECOG performance status, and sex.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Risk Difference (RD)","paramValue":"-2.90","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.26","ciUpperLimit":"3.45"}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response (DOR) was calculated as the time from the first objective response (PR or CR) to disease progression per RECIST v1.1 based on the central, independent, blinded radiologists' review.\n\nDOR was only calculated for participants with an objective response. For responders not meeting the criterion for progression by the end of the study, DOR was censored at the date of the last evaluable tumor assessment.\n\nProgressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm, or, unequivocal progression of existing non-target lesions, or any new lesions.","populationDescription":"Intent-to-treat population with an objective response","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.","groups":[{"id":"OG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"OG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"131"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"4.9","upperLimit":"7.7"},{"groupId":"OG001","value":"5.6","lowerLimit":"5.1","upperLimit":"6.3"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression using RECIST v1.1 based on the central, independent, blinded radiologists' review, or death. Participants who were alive and did not meet the criteria for progression by the end of the study were censored at their last evaluable disease assessment date. Participants with no evaluable tumor assessments after randomization who did not die by the end of the study were censored on the randomization date.\n\nProgressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm, or, unequivocal progression of existing non-target lesions, or any new lesions.","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until the end of study; The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.","groups":[{"id":"OG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"OG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"314"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","lowerLimit":"6.3","upperLimit":"7.9"},{"groupId":"OG001","value":"7.9","lowerLimit":"6.6","upperLimit":"8.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The hazard ratio for ABP 215 relative to bevacizumab was based on a stratified Cox proportional hazards model. Stratification factors are geographic region, ECOG performance status, and sex.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.03","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"1.29"}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"Adverse events (AEs) were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4, and according to the following scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death due to AE.\n\nA serious adverse event (SAE) is defined as an AE that meets at least 1 of the following serious criteria:\n\n* fatal\n* life-threatening\n* required inpatient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event","populationDescription":"Safety analysis population consisted of all participants who received any amount of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"up to 19 weeks","groups":[{"id":"OG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"OG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"309"}]}],"classes":[{"title":"Any adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"308"},{"groupId":"OG001","value":"289"}]}]},{"title":"Any grade ≥ 3 adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"137"}]}]},{"title":"Any fatal adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"}]}]},{"title":"Any serious adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"71"}]}]},{"title":"Any AE leading to discontinuation of study drug","categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"53"}]}]},{"title":"Any AE leading to discontinuation of chemotherapy","categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"59"}]}]},{"title":"Any AE leading to dose delay of study drug","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"69"}]}]},{"title":"Any AE leading to dose delay of any chemotherapy","categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"83"}]}]},{"title":"Any AE leading to dose reduction of chemotherapy","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"49"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Developed Anti-drug Antibodies","description":"Two validated assays were used to detect the presence of anti-ABP 215 antibodies. Samples were first tested in an electrochemiluminescence (ECL)- based bridging immunoassay to detect antibodies capable of binding to ABP 215 (Binding Antibody Assay). Samples confirmed to be positive for binding antibodies were subsequently tested in a non-cell based target binding assay to determine neutralizing activity against ABP 215 (Neutralizing Antibody Assay). If a post-dose sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the sample was defined as positive for neutralizing antibodies.","populationDescription":"Safety analysis population with available data","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"44 weeks (6 months after end of treatment)","groups":[{"id":"OG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"OG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"294"},{"groupId":"OG001","value":"284"}]}],"classes":[{"title":"Binding antibody positive","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}]}]},{"title":"Neutralizing antibody positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival (OS) was defined as the time from the randomization date to date of death. Participants alive at the end of study were censored at the last date known to be alive, derived from dates collected within the study that implied a participant was alive.\n\nParticipants were followed for survival status during the treatment phase and thereafter every 9 weeks until the end of the clinical study, consent was withdrawn, they were lost to follow-up, died, or had proscribed therapy (eg, commercial bevacizumab, non-study anti-cancer treatment).","populationDescription":"Safety analysis population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until the end of study; The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.","groups":[{"id":"OG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."},{"id":"OG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"309"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Could not be estimated due to the low number of deaths"},{"groupId":"OG001","value":"NA","lowerLimit":"14.6","upperLimit":"NA","comment":"Could not be estimated due to the low number of deaths"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Hazard ratio for ABP 215 relative to bevacizumab, based on a stratified Cox proportional hazards model. Stratification factors are geographic region, ECOG performance status, and sex.","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.10","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.75","ciUpperLimit":"1.61"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"19 weeks","description":"Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","eventGroups":[{"id":"EG000","title":"ABP 215","description":"Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.","seriousNumAffected":85,"seriousNumAtRisk":324,"otherNumAffected":286,"otherNumAtRisk":324},{"id":"EG001","title":"Bevacizumab","description":"Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.","seriousNumAffected":71,"seriousNumAtRisk":309,"otherNumAffected":276,"otherNumAtRisk":309}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":324},{"groupId":"EG001","numAffected":6,"numAtRisk":309}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":324},{"groupId":"EG001","numAffected":8,"numAtRisk":309}]},{"term":"Hypercoagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":324},{"groupId":"EG001","numAffected":3,"numAtRisk":309}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":2,"numAtRisk":309}]},{"term":"Acute left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Paroxysmal arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Anal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":324},{"groupId":"EG001","numAffected":2,"numAtRisk":309}]},{"term":"Diarrhoea haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Large intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Mesenteric artery embolism","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":2,"numAtRisk":309}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":2,"numAtRisk":309}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Abscess soft tissue","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Bronchopulmonary aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Cytomegalovirus hepatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":2,"numAtRisk":309}]},{"term":"Escherichia bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Neutropenic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":2,"numAtRisk":309}]},{"term":"Pilonidal cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":324},{"groupId":"EG001","numAffected":5,"numAtRisk":309}]},{"term":"Pseudomonas infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":2,"numAtRisk":309}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Brain contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":2,"numAtRisk":309}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Ischaemic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Hallucinations, mixed","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Bronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":324},{"groupId":"EG001","numAffected":4,"numAtRisk":309}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":324},{"groupId":"EG001","numAffected":5,"numAtRisk":309}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Pulmonary artery thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":324},{"groupId":"EG001","numAffected":6,"numAtRisk":309}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Rash generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Subcutaneous emphysema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Prophylaxis","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Embolism arterial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":309}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":309}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":65,"numAtRisk":324},{"groupId":"EG001","numAffected":60,"numAtRisk":309}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":324},{"groupId":"EG001","numAffected":23,"numAtRisk":309}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":55,"numAtRisk":324},{"groupId":"EG001","numAffected":60,"numAtRisk":309}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":324},{"groupId":"EG001","numAffected":43,"numAtRisk":309}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":324},{"groupId":"EG001","numAffected":36,"numAtRisk":309}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":324},{"groupId":"EG001","numAffected":55,"numAtRisk":309}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":324},{"groupId":"EG001","numAffected":19,"numAtRisk":309}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":82,"numAtRisk":324},{"groupId":"EG001","numAffected":95,"numAtRisk":309}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":324},{"groupId":"EG001","numAffected":18,"numAtRisk":309}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":324},{"groupId":"EG001","numAffected":41,"numAtRisk":309}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":324},{"groupId":"EG001","numAffected":42,"numAtRisk":309}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":324},{"groupId":"EG001","numAffected":59,"numAtRisk":309}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":324},{"groupId":"EG001","numAffected":20,"numAtRisk":309}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":324},{"groupId":"EG001","numAffected":16,"numAtRisk":309}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":324},{"groupId":"EG001","numAffected":42,"numAtRisk":309}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":324},{"groupId":"EG001","numAffected":29,"numAtRisk":309}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":324},{"groupId":"EG001","numAffected":19,"numAtRisk":309}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":324},{"groupId":"EG001","numAffected":25,"numAtRisk":309}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":324},{"groupId":"EG001","numAffected":44,"numAtRisk":309}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":324},{"groupId":"EG001","numAffected":20,"numAtRisk":309}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":324},{"groupId":"EG001","numAffected":25,"numAtRisk":309}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":324},{"groupId":"EG001","numAffected":24,"numAtRisk":309}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":324},{"groupId":"EG001","numAffected":38,"numAtRisk":309}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":324},{"groupId":"EG001","numAffected":40,"numAtRisk":309}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":324},{"groupId":"EG001","numAffected":16,"numAtRisk":309}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":324},{"groupId":"EG001","numAffected":22,"numAtRisk":309}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":324},{"groupId":"EG001","numAffected":19,"numAtRisk":309}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":324},{"groupId":"EG001","numAffected":21,"numAtRisk":309}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":324},{"groupId":"EG001","numAffected":24,"numAtRisk":309}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":324},{"groupId":"EG001","numAffected":39,"numAtRisk":309}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":140,"numAtRisk":324},{"groupId":"EG001","numAffected":127,"numAtRisk":309}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":324},{"groupId":"EG001","numAffected":41,"numAtRisk":309}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."},"pointOfContact":{"title":"Study Director","organization":"Amgen Inc.","phone":"866-572-6436"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Canada","Czechia","Germany","Greece","Hong Kong","Hungary","Italy","Mexico","Netherlands","Poland","Romania","Russia","Spain","Taiwan"]},"interventionBrowseModule":{"meshes":[{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000068258","term":"Bevacizumab"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}